Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2018
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
110,393
+13.44%
|
$5,961,222
$54.72 P/Share
|
|
Feb 27
2018
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
34,931
+20.09%
|
$1,886,274
$54.72 P/Share
|
|
Feb 27
2018
|
Ashley Watson SVP Chief Ethics & Com Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,322
+50.0%
|
$125,388
$54.72 P/Share
|
|
Feb 27
2018
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Grant, award, or other acquisition
|
Direct |
13,949
+11.78%
|
$753,246
$54.72 P/Share
|
|
Feb 27
2018
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
4,522
+8.58%
|
$244,188
$54.72 P/Share
|
|
Feb 27
2018
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,062
+14.09%
|
$489,348
$54.72 P/Share
|
|
Feb 27
2018
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
12,575
+18.5%
|
$679,050
$54.72 P/Share
|
|
Feb 27
2018
|
Michael J Holston EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
20,694
+22.87%
|
$1,117,476
$54.72 P/Share
|
|
Feb 27
2018
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
30,908
+22.55%
|
$1,669,032
$54.72 P/Share
|
|
Feb 27
2018
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
3,090
+13.86%
|
$166,860
$54.72 P/Share
|
|
Feb 09
2018
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Payment of exercise price or tax liability
|
Direct |
2,974
-6.5%
|
$160,596
$54.73 P/Share
|
|
Feb 09
2018
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
8,572
+15.77%
|
-
|
|
Feb 09
2018
|
Wendell P Weeks Director |
SELL
Open market or private sale
|
Direct |
5,000
-98.04%
|
$265,000
$53.57 P/Share
|
|
Feb 09
2018
|
Wendell P Weeks Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
$190,000
$38.04 P/Share
|
|
Jan 16
2018
|
Michael J Holston EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
12,500
-20.29%
|
$762,500
$61.63 P/Share
|
|
Jan 16
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Indirect |
50,608
-44.64%
|
$3,087,088
$61.63 P/Share
|
|
Jan 16
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
50,994
-100.0%
|
$3,110,634
$61.63 P/Share
|
|
Jan 16
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
50,994
+50.0%
|
$1,835,784
$36.56 P/Share
|
|
Jan 16
2018
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
60,000
-20.48%
|
$3,660,000
$61.63 P/Share
|
|
Jan 16
2018
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Exercise of conversion of derivative security
|
Direct |
52,000
+25.31%
|
$2,288,000
$44.3 P/Share
|
|
Jan 12
2018
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
5,000
-4.7%
|
$290,000
$58.0 P/Share
|
|
Dec 15
2017
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Bona fide gift
|
Indirect |
750
-0.66%
|
-
|
|
Nov 08
2017
|
Thomas H Glocer Director |
SELL
Open market or private sale
|
Direct |
5,000
-49.51%
|
$280,000
$56.2 P/Share
|
|
Nov 08
2017
|
Thomas H Glocer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+33.11%
|
$190,000
$38.04 P/Share
|
|
May 12
2017
|
C Robert Kidder Director |
SELL
Open market or private sale
|
Direct |
5,000
-34.92%
|
$315,000
$63.54 P/Share
|
|
May 12
2017
|
C Robert Kidder Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+25.88%
|
$175,000
$35.19 P/Share
|
|
May 09
2017
|
Robert M Davis Chairman, CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
44,530
-37.73%
|
$2,849,920
$64.01 P/Share
|
|
May 09
2017
|
Robert M Davis Chairman, CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
85,881
+42.12%
|
-
|
|
May 09
2017
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
960
-4.06%
|
$61,440
$64.01 P/Share
|
|
May 09
2017
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,576
+9.82%
|
-
|
|
May 09
2017
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
960
-5.62%
|
$61,440
$64.01 P/Share
|
|
May 09
2017
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
2,576
+13.11%
|
-
|
|
May 02
2017
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,078
-2.32%
|
$66,836
$62.38 P/Share
|
|
May 02
2017
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,092
+6.25%
|
-
|
|
May 02
2017
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Payment of exercise price or tax liability
|
Direct |
974
-2.23%
|
$60,388
$62.38 P/Share
|
|
May 02
2017
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
3,092
+6.62%
|
-
|
|
Apr 03
2017
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Indirect |
53,850
-31.64%
|
$3,392,550
$63.48 P/Share
|
|
Feb 27
2017
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,795
+11.78%
|
$181,675
$65.85 P/Share
|
|
Feb 27
2017
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
3,758
+8.54%
|
$244,270
$65.85 P/Share
|
|
Feb 27
2017
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
31,913
+50.0%
|
$2,074,345
$65.85 P/Share
|
|
Feb 27
2017
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
11,771
+24.59%
|
$765,115
$65.85 P/Share
|
|
Feb 27
2017
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
101,552
+14.47%
|
$6,600,880
$65.85 P/Share
|
|
Feb 27
2017
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,707
+7.93%
|
$240,955
$65.85 P/Share
|
|
Feb 27
2017
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Grant, award, or other acquisition
|
Direct |
16,995
+13.76%
|
$1,104,675
$65.85 P/Share
|
|
Feb 27
2017
|
Michael J Holston EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
12,159
+16.3%
|
$790,335
$65.85 P/Share
|
|
Feb 27
2017
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,797
+16.2%
|
$181,805
$65.85 P/Share
|
|
Feb 27
2017
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
32,670
+24.33%
|
$2,123,550
$65.85 P/Share
|
|
Feb 27
2017
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
39,970
+50.0%
|
$2,598,050
$65.85 P/Share
|
|
Feb 14
2017
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Open market or private sale
|
Direct |
2,954
-20.19%
|
$189,056
$64.73 P/Share
|
|
Feb 08
2017
|
Patricia F Russo Director |
SELL
Open market or private sale
|
Direct |
5,000
-27.55%
|
$320,000
$64.42 P/Share
|